Bioreactors Bring Blood Vessel Organoids to Life: Scalable Production of Human Extracellular Vesicles

A breakthrough in biomanufacturing and organoid technology is paving the way for next-generation regenerative medicine. Researchers have successfully used a vertical wheel bioreactor to culture human blood vessel organoids (BVOs) that continuously secrete extracellular vesicles (EVs)—tiny, information-rich particles crucial for cell communication and therapeutic applications.

Why Extracellular Vesicles Matter

Extracellular vesicles, or EVs, are nano-sized lipid-based packages released by cells. They carry proteins, lipids, and RNA molecules that can influence the behavior of other cells. Because of their natural compatibility with human biology, EVs are increasingly being explored as drug delivery vehicles, biomarkers, and regenerative agents in tissue repair.

However, producing EVs at scale has been a major challenge—until now.

Scaling Up EV Production

In this study, researchers grew blood vessel organoids derived from human stem cells inside a vertical wheel bioreactor, a system that maintains a gentle, uniform flow to keep organoids healthy and well-nourished.

Compared to static culture systems, the bioreactor environment:

Enhanced organoid growth and maturation
Increased extracellular vesicle secretion
Improved EV lipid composition and quality consistency

This setup allows for continuous EV harvesting, marking a step toward scalable and standardized biomanufacturing of human-derived vesicles.

Lipidomics Reveals Vesicle Identity

Through lipidomics analysis, the study identified unique lipid profiles of EVs secreted by blood vessel organoids. These lipids are essential for maintaining EV structure, targeting, and function. The analysis revealed that EVs from bioreactor-grown organoids had distinct lipid signatures linked to vascular function, suggesting their potential in vascular regeneration and drug delivery.

Impact on Regenerative Medicine

This research bridges two transformative technologies: organoids (miniaturized human organ models) and bioreactors (controlled growth systems). Together, they enable reliable and reproducible production of EVs for medical applications such as:

Tissue regeneration
Vascular disease treatment
Personalized medicine

By scaling production without losing biological quality, the vertical-wheel system brings EV-based therapeutics closer to clinical translation.

Reference

Ene, J., Liu, C., Syed, F., Sun, L., Berry, D., Durairaj, P., Liu, Z. L., Zeng, C., Jung, S., & Li, Y. (2025). Biomanufacturing and lipidomics analysis of extracellular vesicles secreted by human blood vessel organoids in a vertical wheel bioreactor. Stem Cell Research & Therapy, 16(1), 207. https://doi.org/10.1186/s13287-025-04317-2